Collectively, these findings indicate that GA ameliorates CE-induced hepatic fibrosis by targeting the SUMO-Smad4 axis to modulate the immune microenvironment, providing a novel therapeutic strategy. The gene discussed is SMAD4; the disease is Hepatic fibrosis.